Drug Profile
Research programme: inflammatory disease therapeutics - Italfarmaco
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Italfarmaco
- Class
- Mechanism of Action Cytokine modulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Italy (PO)
- 05 Mar 2007 Preclinical trials in Inflammation in Italy (PO)